New studies on retatruded, a dual activator for glucagon-like peptide-1 and GIP, indicate promising findings in treating obesity and type 2 diabetes. Early information from clinical trials point to substantial diminutions in body mass and bettered glucose levels. Ongoing research is centered on long-term harmlessness and usefulness, as well as anti